RxDoctor Payments Data

Steven Greenhaw, MD

Ophthalmology · Valdosta, GANPI 1568449981

Payments from drug & device makers

$619in general payments, 2019–2025

Across 25 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$151
  • Bausch & Lomb Americas Inc.$143
  • Mallinckrodt Hospital Products Inc.$89
  • Aerie Pharmaceuticals, Inc.$85
  • AbbVie$75
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$48
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$60197%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$619 in reported general payments places this provider in the 25th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$152,516
Medicare patients
801
Services billed
7,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$45,112
LumiganBimatoprost127$41,424
RocklatanNetarsudil Mesylat/Latanoprost63$36,281
RhopressaNetarsudil Mesylate33$21,611
SimbrinzaBrinzolamide/Brimonidine Tart53$13,436
CombiganBrimonidine Tartrate/Timolol44$13,073
MieboPerfluorohexyloctane/Pf14$11,782
Cyclosporine15$10,594
Timolol Maleate289$9,120
VyzultaLatanoprostene Bunod28$9,013
Latanoprost821$8,670
Travoprost66$6,521
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat344$6,263
Brimonidine Tartrate254$4,194
Alphagan PBrimonidine Tartrate18$3,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$75$103,223247 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$85$57,89296 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$143$20,79642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →